Catalyst Biosciences, Inc.

158 articles with Catalyst Biosciences, Inc.

• Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting

  3/6/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the presentation of a poster, in collaboration with partner Mosaic Biosciences, at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28-May 2, 2019.

• Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress

  2/8/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), presented updated interim data from the Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) currently being developed for the treatment of hemophilia A or B with inhibitors. The data were delivered in an oral presentation at the 12TH Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held Feb. 6-8, 2019 in Prague.

• Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B

  2/6/2019

  atalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications presented preclinical proof-of-concept data of CB 2679d-GT Factor IX gene therapy in hemophilia B mice. 

• Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference

  2/5/2019

  Catalyst Biosciences, Inc. (Nasdaq: CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Annual BIO CEO & Investor Conference, being held in New York City on February 11-12, 2019.

• Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Hemophilia and Allied Disorders

  1/31/2019

  Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced oral and poster presentations at the 12TH Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in Prague from February 6-8, 2019.

• Catalyst Biosciences Announces Proposed Public Offering of Common Stock - Feb. 13, 2018

  2/13/2018

  All of the shares in the offering are to be sold by the Company.

• Catalyst Biosciences Announces Pricing of Public Offering of Common Stock - Feb. 13, 2018

  2/13/2018

  Additionally, the Company has granted the underwriters an option to purchase up to an additional 441,176 shares of its common stock, at the price to the public.

• Catalyst Biosciences Announces Positive Top-Line Data from Phase I/II Study of Subcutaneous CB 2679d/ISU304 in Individuals With Hemophilia B

  2/9/2018

  Results from the trial showed a continuous linear increase in Factor IX activity levels following daily dosing of CB 2679d for six days.

• Catalyst Biosciences Initiates Phase II/III Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B With Inhibitors

  1/4/2018

  This Phase 2 open-label, subcutaneous efficacy trial in individuals with hemophilia A or B with inhibitors will evaluate the ability of MarzAA to eliminate, or minimize, spontaneous bleeding episodes.

• Catalyst Biosciences Announces Closing of Public Offering of Common Stock

  12/27/2017

  JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. are acting as Joint Book-running Managers and LifeSci Capital LLC is acting as a Co-Manager for the proposed offering.

• Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

  12/21/2017

  Catalyst Biosciences today announced the pricing of an underwritten public offering of 1,105,263 shares of its common stock, offered at a price of $9.50 per share to the public.

• Catalyst Biosciences Announces Proposed Public Offering of Common Stock

  12/20/2017

  The Company anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion and to meet working capital needs.

• Catalyst Biosciences Announces Acceleration of Phase I/II Trial of CB 2679d/ISU304 in Individuals with Hemophilia B

  12/18/2017

  Catalyst Biosciences today announces that the Korean MFDS has approved a protocol amendment to omit single dose Cohort 4 and move directly to multi-dose Cohort 5 at 150 IU/kg daily, in the ongoing Phase 1/2 multi-dose study of CB 2679d/ISU304, Catalyst's highly potent next-generation coagulation Factor IX variant in individuals with severe hemophilia B.

• Catalyst Biosciences Announces Appointment of Edward Williams to Its Board of Directors

  12/14/2017

  Mr. Williams was most recently senior vice president of biopharmaceuticals at Novo Nordisk.

• Catalyst Biosciences Announces Interim Phase I/II CB 2679d/ISU304 Results at the American Society of Hematology Conference

  12/11/2017

  The data demonstrate that subcutaneous delivery of CB 2679d significantly increases the factor IX (FIX) activity half-life to 98.7 hours.

• Catalyst Biosciences Strengthens Clinical Hemophilia Programs With Additions to its Senior Leadership Team

  11/28/2017

  The company appointed Arwa Shurrab as vice president of regulatory affairs and Jamie Ellen Siegel, M.D., as the head of clinical development.

• Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update

  11/2/2017

  Cash, cash equivalents and short-term investments, as of Sept. 30, 2017, were $27.5 million.

• Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors

  10/26/2017

  Ms. Hunt was most recently vice president, New Product Gene Therapy, Neuroscience, Oncology, Ophthalmology at Shire.

• Catalyst Biosciences Granted FDA Orphan Drug Designation For Subcutaneous Recombinant Human Factor IX Variant For Treatment Of Hemophilia B

  9/26/2017

• Catalyst Biosciences Announces Successful Completion Of First Subcutaneous Dosing Cohort In Ongoing Hemophilia B Clinical Trial

  9/25/2017